Sepracor Signs Agreement With Eisai To Market Lunesta In Japan
This article was originally published in PharmAsia News
Executive Summary
Eisai will develop and market Sepracor's insomnia treatment Lunesta (eszopiclone) in Japan under an in-licensing agreement announced by the companies July 26